These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 37961028)

  • 21. Recent Advancements in the Design of Nanodelivery Systems of siRNA for Cancer Therapy.
    Yadav DN; Ali MS; Thanekar AM; Pogu SV; Rengan AK
    Mol Pharm; 2022 Dec; 19(12):4506-4526. PubMed ID: 36409653
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor-targeting multifunctional nanoparticles for siRNA delivery: recent advances in cancer therapy.
    Ku SH; Kim K; Choi K; Kim SH; Kwon IC
    Adv Healthc Mater; 2014 Aug; 3(8):1182-93. PubMed ID: 24577795
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RNA Interference-Based Cancer Drugs: The Roadblocks, and the "Delivery" of the Promise.
    Das M; Musetti S; Huang L
    Nucleic Acid Ther; 2019 Apr; 29(2):61-66. PubMed ID: 30562145
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy.
    Miele E; Spinelli GP; Miele E; Di Fabrizio E; Ferretti E; Tomao S; Gulino A
    Int J Nanomedicine; 2012; 7():3637-57. PubMed ID: 22915840
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in siRNA delivery strategies for the treatment of MDR cancer.
    Subhan MA; Attia SA; Torchilin VP
    Life Sci; 2021 Jun; 274():119337. PubMed ID: 33713664
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Strategies for in vivo delivery of siRNAs: recent progress.
    Higuchi Y; Kawakami S; Hashida M
    BioDrugs; 2010 Jun; 24(3):195-205. PubMed ID: 20462284
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comprehensive update of siRNA delivery design strategies for targeted and effective gene silencing in gene therapy and other applications.
    Abosalha AK; Ahmad W; Boyajian J; Islam P; Ghebretatios M; Schaly S; Thareja R; Arora K; Prakash S
    Expert Opin Drug Discov; 2023 Feb; 18(2):149-161. PubMed ID: 36514963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nanoparticulate RNA delivery systems in cancer.
    Sharma A; Jha NK; Dahiya K; Singh VK; Chaurasiya K; Jha AN; Jha SK; Mishra PC; Dholpuria S; Astya R; Nand P; Kumar A; Ruokolainen J; Kesari KK
    Cancer Rep (Hoboken); 2020 Oct; 3(5):e1271. PubMed ID: 32729987
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biomaterials in siRNA Delivery: A Comprehensive Review.
    Ho W; Zhang XQ; Xu X
    Adv Healthc Mater; 2016 Nov; 5(21):2715-2731. PubMed ID: 27700013
    [TBL] [Abstract][Full Text] [Related]  

  • 30. siRNA: Mechanism of action, challenges, and therapeutic approaches.
    Alshaer W; Zureigat H; Al Karaki A; Al-Kadash A; Gharaibeh L; Hatmal MM; Aljabali AAA; Awidi A
    Eur J Pharmacol; 2021 Aug; 905():174178. PubMed ID: 34044011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Construction and Biological Evaluation of a Novel Integrin α
    Chen X; Liu M; Wang R; Yan P; Zhang C; Ma C; Yin L
    Molecules; 2017 Feb; 22(2):. PubMed ID: 28165399
    [TBL] [Abstract][Full Text] [Related]  

  • 32. RNA interference-based therapy and its delivery systems.
    Chen X; Mangala LS; Rodriguez-Aguayo C; Kong X; Lopez-Berestein G; Sood AK
    Cancer Metastasis Rev; 2018 Mar; 37(1):107-124. PubMed ID: 29243000
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cell-Penetrating Peptides Delivering siRNAs: An Overview.
    Falato L; Gestin M; Langel Ü
    Methods Mol Biol; 2021; 2282():329-352. PubMed ID: 33928583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Delivery strategies and potential targets for siRNA in major cancer types.
    Lee SJ; Kim MJ; Kwon IC; Roberts TM
    Adv Drug Deliv Rev; 2016 Sep; 104():2-15. PubMed ID: 27259398
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor-targeted delivery of siRNA by non-viral vector: safe and effective cancer therapy.
    Chen Y; Huang L
    Expert Opin Drug Deliv; 2008 Dec; 5(12):1301-11. PubMed ID: 19040393
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nanoparticle-siRNA: A potential cancer therapy?
    Young SW; Stenzel M; Yang JL
    Crit Rev Oncol Hematol; 2016 Feb; 98():159-69. PubMed ID: 26597018
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [RNA interference (RNAi) and its therapeutic potential in cancer].
    Vázquez-Vega S; Contreras-Paredes A; Lizano-Soberón M; Amador-Molina A; García-Carrancá A; Sánchez-Suárez LP; Benítez-Bribiesca L
    Rev Invest Clin; 2010; 62(1):81-90. PubMed ID: 20415062
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug delivery of siRNA therapeutics: potentials and limits of nanosystems.
    Reischl D; Zimmer A
    Nanomedicine; 2009 Mar; 5(1):8-20. PubMed ID: 18640078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery.
    Gary DJ; Puri N; Won YY
    J Control Release; 2007 Aug; 121(1-2):64-73. PubMed ID: 17588702
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polymeric carrier systems for siRNA delivery.
    Vader P; van der Aa LJ; Storm G; Schiffelers RM; Engbersen JF
    Curr Top Med Chem; 2012; 12(2):108-19. PubMed ID: 22196278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.